{
 "disease": "cutaneous-squamous-cell-carcinoma",
 "label": "Cutaneous squamous cell carcinoma",
 "url": "https://usebiotransfer.org/disease/cutaneous-squamous-cell-carcinoma/",
 "built": "2026-09-17",
 "facts_hash": {
  "answers": "85ab9222f4bb",
  "targets": "409ccd5e475e"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-17",
  "trials": "2026-09-17"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "NOTCH1",
   "ensembl": "ENSG00000148400",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "BRONTICTUZUMAB": "PHASE_1"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "NOTCH2",
   "ensembl": "ENSG00000134250",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "TAREXTUMAB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "EGFR",
   "ensembl": "ENSG00000146648",
   "n_drug_entries": 82,
   "n_distinct_drugs": 74,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "AMIVANTAMAB": "APPROVAL",
    "AUMOLERTINIB": "APPROVAL",
    "AV-412": "PHASE_1",
    "AZD-3759": "PHASE_2_3",
    "AZD-4769": "PHASE_1",
    "BAFISONTAMAB": "PHASE_2",
    "BMS-690514": "PHASE_2",
    "BRIGATINIB": "APPROVAL",
    "CANERTINIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "CETUXIMAB": "APPROVAL",
    "CETUXIMAB SAROTALOCAN": "APPROVAL",
    "CLN-081": "PHASE_3",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DEPATUXIZUMAB": "PHASE_2",
    "DEPATUXIZUMAB MAFODOTIN": "PHASE_3",
    "DULIGOTUZUMAB": "PHASE_2",
    "EPITINIB": "PHASE_1",
    "ERLOTINIB": "APPROVAL",
    "FALNIDAMOL": "PHASE_1",
    "FIRMONERTINIB": "PHASE_3",
    "FUTUXIMAB": "PHASE_3",
    "GC1118": "PHASE_2",
    "GEFITINIB": "APPROVAL",
    "ICOTINIB": "APPROVAL",
    "IMGATUZUMAB": "PHASE_2",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "LAZERTINIB": "APPROVAL",
    "LOSATUXIZUMAB VEDOTIN": "PHASE_1",
    "MAB-425": "UNKNOWN",
    "MATUZUMAB": "PHASE_2",
    "MAVELERTINIB": "PHASE_1_2",
    "MDX-447": "PHASE_1",
    "MOBOCERTINIB": "APPROVAL",
    "MODOTUXIMAB": "PHASE_2",
    "NAQUOTINIB": "PHASE_3",
    "NAZARTINIB": "PHASE_3",
    "NECITUMUMAB": "APPROVAL",
    "NERATINIB": "APPROVAL",
    "NIMOTUZUMAB": "APPROVAL",
    "OLMUTINIB": "APPROVAL",
    "OSIMERTINIB": "APPROVAL",
    "PANITUMUMAB": "APPROVAL",
    "PELITINIB": "PHASE_2",
    "PF-06459988": "PHASE_2",
    "PIMURUTAMAB": "PHASE_2_3",
    "PKI-166": "PHASE_2",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "RINDOPEPIMUT": "PHASE_3",
    "ROCILETINIB": "APPROVAL",
    "RUSERONTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "SIMOTINIB": "PHASE_1",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "THELIATINIB": "PHASE_1",
    "TOMUZOTUXIMAB": "PHASE_2",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZALUTUMUMAB": "PHASE_3"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "AMIVANTAMAB",
    "AUMOLERTINIB",
    "BRIGATINIB",
    "CETUXIMAB",
    "CETUXIMAB SAROTALOCAN",
    "DACOMITINIB",
    "ERLOTINIB",
    "GEFITINIB",
    "ICOTINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "LAZERTINIB",
    "MOBOCERTINIB",
    "NECITUMUMAB",
    "NERATINIB",
    "NIMOTUZUMAB",
    "OLMUTINIB",
    "OSIMERTINIB",
    "PANITUMUMAB",
    "ROCILETINIB",
    "VANDETANIB"
   ],
   "n_approved": 23,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "AMIVANTAMAB": [
     "non-small cell lung carcinoma"
    ],
    "AUMOLERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "BRIGATINIB": [
     "non-small cell lung carcinoma",
     "anaplastic large cell lymphoma"
    ],
    "CETUXIMAB": [
     "malignant tumor of neck",
     "squamous cell carcinoma",
     "colorectal adenocarcinoma",
     "colorectal carcinoma",
     "colorectal cancer",
     "head and neck neoplasm",
     "colorectal neoplasm"
    ],
    "CETUXIMAB SAROTALOCAN": [
     "head and neck cancer"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "ERLOTINIB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ],
    "GEFITINIB": [
     "non-small cell lung carcinoma",
     "head and neck squamous cell carcinoma"
    ],
    "ICOTINIB": [],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "LAZERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "MOBOCERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "NECITUMUMAB": [
     "non-small cell lung carcinoma",
     "colorectal cancer",
     "non-small cell squamous lung carcinoma"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "NIMOTUZUMAB": [
     "head and neck cancer"
    ],
    "OLMUTINIB": [],
    "OSIMERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "PANITUMUMAB": [
     "colorectal cancer",
     "colorectal adenocarcinoma",
     "colorectal neoplasm"
    ],
    "ROCILETINIB": [],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "HRAS",
   "ensembl": "ENSG00000174775",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "SALIRASIB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KMT2D",
   "ensembl": "ENSG00000167548",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "FAT1",
   "ensembl": "ENSG00000083857",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "PDCD1",
   "ensembl": "ENSG00000188389",
   "n_drug_entries": 26,
   "n_distinct_drugs": 26,
   "drugs": {
    "APL-501": "PHASE_2",
    "BALSTILIMAB": "PHASE_3",
    "BUDIGALIMAB": "PHASE_2_3",
    "CADONILIMAB": "PHASE_3",
    "CAMRELIZUMAB": "PHASE_3",
    "CEMIPLIMAB": "APPROVAL",
    "CETRELIMAB": "PHASE_3",
    "CS-1003": "PHASE_3",
    "DOSTARLIMAB": "APPROVAL",
    "FINOTONLIMAB": "PHASE_3",
    "LOMVASTOMIG": "PHASE_2",
    "NIVOLUMAB": "APPROVAL",
    "PEMBROLIZUMAB": "APPROVAL",
    "PENPULIMAB": "PHASE_3",
    "PIDILIZUMAB": "PHASE_2",
    "PIMIVALIMAB": "PHASE_2",
    "PUCOTENLIMAB": "PHASE_3",
    "RETIFANLIMAB": "APPROVAL",
    "SASANLIMAB": "PHASE_3",
    "SERPLULIMAB": "APPROVAL",
    "SINTILIMAB": "APPROVAL",
    "SPARTALIZUMAB": "PHASE_3",
    "TEBOTELIMAB": "PHASE_2_3",
    "TISLELIZUMAB": "APPROVAL",
    "TORIPALIMAB": "APPROVAL",
    "ZIMBERELIMAB": "PHASE_3"
   },
   "approved": [
    "CEMIPLIMAB",
    "DOSTARLIMAB",
    "NIVOLUMAB",
    "PEMBROLIZUMAB",
    "RETIFANLIMAB",
    "SERPLULIMAB",
    "SINTILIMAB",
    "TISLELIZUMAB",
    "TORIPALIMAB"
   ],
   "n_approved": 9,
   "approved_for": {
    "CEMIPLIMAB": [
     "squamous cell carcinoma",
     "basal cell carcinoma",
     "cutaneous squamous cell carcinoma",
     "cervical cancer"
    ],
    "DOSTARLIMAB": [
     "endometrial cancer",
     "endometrial neoplasm"
    ],
    "NIVOLUMAB": [
     "head and neck cancer",
     "pleural mesothelioma",
     "gastric cancer",
     "melanoma",
     "non-small cell lung carcinoma",
     "renal cell carcinoma",
     "transitional cell carcinoma",
     "colorectal neoplasm",
     "Hodgkins lymphoma",
     "mesothelioma",
     "head and neck squamous cell carcinoma",
     "classic Hodgkin lymphoma",
     "metastatic melanoma"
    ],
    "PEMBROLIZUMAB": [
     "melanoma",
     "metastatic melanoma",
     "endometrium neoplasm",
     "head and neck squamous cell carcinoma",
     "transitional cell carcinoma",
     "renal cell carcinoma",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma"
    ],
    "RETIFANLIMAB": [
     "neuroendocrine carcinoma",
     "Merkel cell skin cancer",
     "squamous cell carcinoma"
    ],
    "SERPLULIMAB": [
     "esophageal squamous cell carcinoma",
     "non-small cell lung carcinoma",
     "small cell lung carcinoma"
    ],
    "SINTILIMAB": [
     "Hodgkins lymphoma"
    ],
    "TISLELIZUMAB": [
     "esophageal cancer",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma",
     "adenocarcinoma",
     "esophageal squamous cell carcinoma",
     "gastric neoplasm"
    ],
    "TORIPALIMAB": [
     "melanoma",
     "nasopharyngeal carcinoma",
     "urothelial carcinoma",
     "esophageal squamous cell carcinoma",
     "Niemann-Pick disease type B"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CD274",
   "ensembl": "ENSG00000120217",
   "n_drug_entries": 13,
   "n_distinct_drugs": 13,
   "drugs": {
    "ADEBRELIMAB": "PHASE_3",
    "ATEZOLIZUMAB": "APPROVAL",
    "AVELUMAB": "APPROVAL",
    "BINTRAFUSP ALFA": "PHASE_3",
    "COSIBELIMAB": "APPROVAL",
    "DANBURSTOTUG": "PHASE_2",
    "DURVALUMAB": "APPROVAL",
    "ENVAFOLIMAB": "PHASE_3",
    "ERFONRILIMAB": "PHASE_3",
    "INCB-086550": "PHASE_2",
    "PACMILIMAB": "PHASE_2",
    "SOCAZOLIMAB": "PHASE_3",
    "SUGEMALIMAB": "APPROVAL"
   },
   "approved": [
    "ATEZOLIZUMAB",
    "AVELUMAB",
    "COSIBELIMAB",
    "DURVALUMAB",
    "SUGEMALIMAB"
   ],
   "n_approved": 5,
   "approved_for": {
    "ATEZOLIZUMAB": [
     "urothelial carcinoma",
     "non-small cell lung carcinoma",
     "breast cancer",
     "small cell lung carcinoma",
     "breast neoplasm",
     "transitional cell carcinoma"
    ],
    "AVELUMAB": [
     "Merkel cell skin cancer",
     "urothelial carcinoma",
     "neuroendocrine neoplasm"
    ],
    "COSIBELIMAB": [
     "head and neck squamous cell carcinoma"
    ],
    "DURVALUMAB": [
     "non-small cell lung carcinoma",
     "small cell lung carcinoma",
     "urothelial carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUGEMALIMAB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "TGFBR1",
   "ensembl": "ENSG00000106799",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "GALUNISERTIB": "PHASE_2_3",
    "VACTOSERTIB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CASP8",
   "ensembl": "ENSG00000064012",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "EMRICASAN": "PHASE_2",
    "NIVOCASAN": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "PD-1": {
    "n": 97,
    "n_observational": 8,
    "n_active": 53,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT04204837",
      "title": "Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin",
      "status": "RECRUITING",
      "last_update": "2024-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04389632",
      "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04429542",
      "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04975152",
      "title": "Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025813",
      "title": "Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2022-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076760",
      "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05136196",
      "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05669430",
      "title": "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06171750",
      "title": "Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06177106",
      "title": "SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06265285",
      "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "status": "RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06288191",
      "title": "Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06585410",
      "title": "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06589804",
      "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06823479",
      "title": "Towards Cure Via Only Ultra-short ICB in CSCC",
      "status": "RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06868433",
      "title": "TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094685",
      "title": "Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07115043",
      "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07426484",
      "title": "Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749586",
      "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02721732",
      "title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02760498",
      "title": "Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02883556",
      "title": "Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin",
      "status": "COMPLETED",
      "last_update": "2021-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02955290",
      "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02964559",
      "title": "Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2024-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03057613",
      "title": "The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03082534",
      "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277352",
      "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03284424",
      "title": "Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)",
      "status": "COMPLETED",
      "last_update": "2024-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03291002",
      "title": "Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC",
      "status": "UNKNOWN",
      "last_update": "2021-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03565783",
      "title": "Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03590054",
      "title": "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03633110",
      "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03773744",
      "title": "MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2021-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03833167",
      "title": "Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)",
      "status": "COMPLETED",
      "last_update": "2026-03-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03834233",
      "title": "Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03889912",
      "title": "Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-01-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03894618",
      "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
      "status": "COMPLETED",
      "last_update": "2025-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03901573",
      "title": "High-Risk Skin Cancers With Atezolizumab Plus NT-I7",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03969004",
      "title": "Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007744",
      "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04050436",
      "title": "Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04154943",
      "title": "Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04242173",
      "title": "Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC",
      "status": "TERMINATED",
      "last_update": "2022-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04242199",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04272034",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04301011",
      "title": "Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04305795",
      "title": "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04315701",
      "title": "A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04339062",
      "title": "Cemiplimab in AlloSCT/SOT Recipients With CSCC",
      "status": "COMPLETED",
      "last_update": "2025-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04348916",
      "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04428671",
      "title": "Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04454489",
      "title": "Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition",
      "status": "COMPLETED",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04576091",
      "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04616248",
      "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04620200",
      "title": "Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04632433",
      "title": "Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799054",
      "title": "A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04808999",
      "title": "Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04812535",
      "title": "Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.",
      "status": "TERMINATED",
      "last_update": "2025-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913220",
      "title": "A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)",
      "status": "TERMINATED",
      "last_update": "2026-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916002",
      "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05220748",
      "title": "RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC",
      "status": "WITHDRAWN",
      "last_update": "2023-04-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256381",
      "title": "A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05490485",
      "title": "Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05574101",
      "title": "A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05721755",
      "title": "Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05729139",
      "title": "Cemiplimab/Peg-Interferon-\u03b1 in Advanced CSCC",
      "status": "WITHDRAWN",
      "last_update": "2023-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05878288",
      "title": "Deep sequencIng in Cutaneous Squamous CEll caRciNomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06014086",
      "title": "Intratumoral PH-762 for Cutaneous Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06036836",
      "title": "Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)",
      "status": "COMPLETED",
      "last_update": "2026-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041802",
      "title": "A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06295809",
      "title": "A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)",
      "status": "TERMINATED",
      "last_update": "2026-05-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06384820",
      "title": "Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)",
      "status": "WITHDRAWN",
      "last_update": "2024-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06418724",
      "title": "Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06568172",
      "title": "Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer",
      "status": "SUSPENDED",
      "last_update": "2026-09-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06580054",
      "title": "Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07715734",
      "title": "Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-1",
     "cemiplimab",
     "Libtayo",
     "pembrolizumab",
     "nivolumab",
     "cosibelimab",
     "Unloxcyt"
    ]
   },
   "PD-L1": {
    "n": 30,
    "n_observational": 1,
    "n_active": 12,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05085496",
      "title": "Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC",
      "status": "RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06177106",
      "title": "SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06305962",
      "title": "177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07426484",
      "title": "Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02883556",
      "title": "Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin",
      "status": "COMPLETED",
      "last_update": "2021-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02955290",
      "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03082534",
      "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03108131",
      "title": "Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03284424",
      "title": "Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)",
      "status": "COMPLETED",
      "last_update": "2024-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03590054",
      "title": "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03833167",
      "title": "Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)",
      "status": "COMPLETED",
      "last_update": "2026-03-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03901573",
      "title": "High-Risk Skin Cancers With Atezolizumab Plus NT-I7",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04710498",
      "title": "Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04812535",
      "title": "Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.",
      "status": "TERMINATED",
      "last_update": "2025-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916002",
      "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063552",
      "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05110781",
      "title": "Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site",
      "status": "TERMINATED",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05888844",
      "title": "A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06036836",
      "title": "Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)",
      "status": "COMPLETED",
      "last_update": "2026-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041802",
      "title": "A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06418724",
      "title": "Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-L1",
     "cosibelimab",
     "atezolizumab"
    ]
   },
   "EGFR": {
    "n": 33,
    "n_observational": 2,
    "n_active": 10,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04429542",
      "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05747625",
      "title": "(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05910827",
      "title": "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06589804",
      "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054691",
      "title": "ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin",
      "status": "COMPLETED",
      "last_update": "2015-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00126555",
      "title": "Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2019-08-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00240682",
      "title": "Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR",
      "status": "COMPLETED",
      "last_update": "2012-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00369512",
      "title": "A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00423397",
      "title": "Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00954226",
      "title": "Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01059305",
      "title": "Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin",
      "status": "TERMINATED",
      "last_update": "2017-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01129154",
      "title": "Panitumumab (Vectibix\u00ae) in Cutaneous Squamous Cell Carcinoma (SCC)",
      "status": "UNKNOWN",
      "last_update": "2010-08-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01198028",
      "title": "Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01465815",
      "title": "Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)",
      "status": "WITHDRAWN",
      "last_update": "2014-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01979211",
      "title": "Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck",
      "status": "COMPLETED",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02324608",
      "title": "Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2023-12-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03082534",
      "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03114319",
      "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03421912",
      "title": "Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)",
      "status": "COMPLETED",
      "last_update": "2021-07-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03524326",
      "title": "Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03944941",
      "title": "Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04163952",
      "title": "Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin",
      "status": "TERMINATED",
      "last_update": "2026-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04305795",
      "title": "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916002",
      "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04985825",
      "title": "Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063552",
      "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05238363",
      "title": "The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)",
      "status": "UNKNOWN",
      "last_update": "2022-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05827614",
      "title": "Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications",
      "status": "TERMINATED",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06418724",
      "title": "Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07042295",
      "title": "Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System",
      "status": "SUSPENDED",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07394244",
      "title": "Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07715734",
      "title": "Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "EGFR",
     "cetuximab",
     "panitumumab",
     "erlotinib",
     "gefitinib"
    ]
   },
   "CTLA-4": {
    "n": 8,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06823479",
      "title": "Towards Cure Via Only Ultra-short ICB in CSCC",
      "status": "RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04620200",
      "title": "Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab"
    ]
   },
   "oncolytic": {
    "n": 8,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03458117",
      "title": "T-VEC in Non-melanoma Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2022-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03714828",
      "title": "Study of TVEC in Patients With Cutaneous Squamous Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2024-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04050436",
      "title": "Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04163952",
      "title": "Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin",
      "status": "TERMINATED",
      "last_update": "2026-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04349436",
      "title": "Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05858229",
      "title": "Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "RP1",
     "vusolimogene",
     "talimogene",
     "T-VEC"
    ]
   },
   "TIL": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07288073",
      "title": "TIL Therapy in cSCC and MCC",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "tumor-infiltrating lymphocytes",
     "lifileucel"
    ]
   },
   "intralesional": {
    "n": 44,
    "n_observational": 1,
    "n_active": 19,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03889899",
      "title": "Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04068155",
      "title": "Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04534127",
      "title": "Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia",
      "status": "RECRUITING",
      "last_update": "2026-06-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076760",
      "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06171750",
      "title": "Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06585410",
      "title": "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06615635",
      "title": "Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06664151",
      "title": "A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07228442",
      "title": "L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07339176",
      "title": "Intratumoral N17350 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002963",
      "title": "Photodynamic Therapy in Treating Patients With Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01017185",
      "title": "Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions",
      "status": "COMPLETED",
      "last_update": "2019-05-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01984892",
      "title": "Treatment of Solid Tumors With Intratumoral Hiltonol\u00ae (Poly-ICLC)",
      "status": "TERMINATED",
      "last_update": "2018-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02988960",
      "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03291002",
      "title": "Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC",
      "status": "UNKNOWN",
      "last_update": "2021-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03353077",
      "title": "Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)",
      "status": "COMPLETED",
      "last_update": "2021-03-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03458117",
      "title": "T-VEC in Non-melanoma Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2022-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03737734",
      "title": "Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03773744",
      "title": "MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2021-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03886181",
      "title": "Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)",
      "status": "TERMINATED",
      "last_update": "2025-12-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03889912",
      "title": "Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-01-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03982212",
      "title": "A Window of Opportunity Trial of Intratumoral Injection of Copaxone\u00ae in Patients With Percutaneously Accessible Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04050436",
      "title": "Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04160065",
      "title": "Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers",
      "status": "COMPLETED",
      "last_update": "2024-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04293679",
      "title": "Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC",
      "status": "COMPLETED",
      "last_update": "2022-06-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04301011",
      "title": "Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04348916",
      "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04362722",
      "title": "Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04502888",
      "title": "Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin",
      "status": "TERMINATED",
      "last_update": "2025-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04540588",
      "title": "Retreatment With Intratumoral Diffusing Alpha Radiation Emitters",
      "status": "COMPLETED",
      "last_update": "2025-12-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844983",
      "title": "A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916002",
      "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04925713",
      "title": "IFx-Hu2.0 for the Treatment of Patients With Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2024-08-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05323253",
      "title": "Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05329792",
      "title": "L19IL2/L19TNF in Skin Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05421013",
      "title": "Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05858229",
      "title": "Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06014086",
      "title": "Intratumoral PH-762 for Cutaneous Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07100925",
      "title": "A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07144384",
      "title": "Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-29",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "intralesional",
     "intratumoral"
    ]
   }
  },
  "by_drug": {
   "AFATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05070403",
      "title": "Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AFATINIB DIMALEATE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05070403",
      "title": "Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AMIVANTAMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07042295",
      "title": "Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System",
      "status": "SUSPENDED",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ATEZOLIZUMAB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05085496",
      "title": "Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC",
      "status": "RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03108131",
      "title": "Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03901573",
      "title": "High-Risk Skin Cancers With Atezolizumab Plus NT-I7",
      "status": "TERMINATED",
      "last_update": "2025-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04710498",
      "title": "Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063552",
      "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05110781",
      "title": "Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site",
      "status": "TERMINATED",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AVELUMAB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03737721",
      "title": "The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy",
      "status": "TERMINATED",
      "last_update": "2025-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03944941",
      "title": "Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BUDIGALIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02988960",
      "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CAMRELIZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05490485",
      "title": "Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEMIPLIMAB": {
    "n": 26,
    "n_observational": 7,
    "n_active": 15,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04975152",
      "title": "Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06171750",
      "title": "Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06585410",
      "title": "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02760498",
      "title": "Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03565783",
      "title": "Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03889912",
      "title": "Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-01-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03969004",
      "title": "Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04050436",
      "title": "Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04154943",
      "title": "Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04242173",
      "title": "Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC",
      "status": "TERMINATED",
      "last_update": "2022-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04305795",
      "title": "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04315701",
      "title": "A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04339062",
      "title": "Cemiplimab in AlloSCT/SOT Recipients With CSCC",
      "status": "COMPLETED",
      "last_update": "2025-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04428671",
      "title": "Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04632433",
      "title": "Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913220",
      "title": "A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)",
      "status": "TERMINATED",
      "last_update": "2026-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916002",
      "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05574101",
      "title": "A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05729139",
      "title": "Cemiplimab/Peg-Interferon-\u03b1 in Advanced CSCC",
      "status": "WITHDRAWN",
      "last_update": "2023-08-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05878288",
      "title": "Deep sequencIng in Cutaneous Squamous CEll caRciNomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06384820",
      "title": "Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)",
      "status": "WITHDRAWN",
      "last_update": "2024-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06418724",
      "title": "Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06568172",
      "title": "Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer",
      "status": "SUSPENDED",
      "last_update": "2026-09-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07715734",
      "title": "Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CETUXIMAB": {
    "n": 13,
    "n_observational": 1,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05910827",
      "title": "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers",
      "status": "RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06589804",
      "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00240682",
      "title": "Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR",
      "status": "COMPLETED",
      "last_update": "2012-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01979211",
      "title": "Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck",
      "status": "COMPLETED",
      "last_update": "2024-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02324608",
      "title": "Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2023-12-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03082534",
      "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03524326",
      "title": "Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03944941",
      "title": "Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05063552",
      "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06418724",
      "title": "Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07042295",
      "title": "Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System",
      "status": "SUSPENDED",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07715734",
      "title": "Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COSIBELIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07426484",
      "title": "Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DACOMITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02268747",
      "title": "Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2016-07-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DURVALUMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ERLOTINIB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00369512",
      "title": "A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00954226",
      "title": "Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01059305",
      "title": "Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin",
      "status": "TERMINATED",
      "last_update": "2017-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01198028",
      "title": "Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01465815",
      "title": "Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)",
      "status": "WITHDRAWN",
      "last_update": "2014-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05827614",
      "title": "Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications",
      "status": "TERMINATED",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GEFITINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00054691",
      "title": "ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin",
      "status": "COMPLETED",
      "last_update": "2015-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00126555",
      "title": "Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2019-08-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00423397",
      "title": "Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IMGATUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04985825",
      "title": "Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MATUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05238363",
      "title": "The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)",
      "status": "UNKNOWN",
      "last_update": "2022-06-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAZARTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03114319",
      "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NIVOLUMAB": {
    "n": 17,
    "n_observational": 0,
    "n_active": 13,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04204837",
      "title": "Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin",
      "status": "RECRUITING",
      "last_update": "2024-04-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076760",
      "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05136196",
      "title": "BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06265285",
      "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "status": "RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06288191",
      "title": "Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06823479",
      "title": "Towards Cure Via Only Ultra-short ICB in CSCC",
      "status": "RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02955290",
      "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03633110",
      "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03834233",
      "title": "Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04620200",
      "title": "Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PANITUMUMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05747625",
      "title": "(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01129154",
      "title": "Panitumumab (Vectibix\u00ae) in Cutaneous Squamous Cell Carcinoma (SCC)",
      "status": "UNKNOWN",
      "last_update": "2010-08-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04163952",
      "title": "Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin",
      "status": "TERMINATED",
      "last_update": "2026-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PEMBROLIZUMAB": {
    "n": 48,
    "n_observational": 0,
    "n_active": 23,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04389632",
      "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04429542",
      "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025813",
      "title": "Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2022-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05669430",
      "title": "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06589804",
      "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06868433",
      "title": "TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749586",
      "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02721732",
      "title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02883556",
      "title": "Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin",
      "status": "COMPLETED",
      "last_update": "2021-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "status": "TERMINATED",
      "last_update": "2023-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02955290",
      "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02964559",
      "title": "Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer",
      "status": "COMPLETED",
      "last_update": "2024-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03057613",
      "title": "The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03082534",
      "title": "Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277352",
      "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03284424",
      "title": "Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)",
      "status": "COMPLETED",
      "last_update": "2024-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03590054",
      "title": "Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03633110",
      "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684785",
      "title": "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03773744",
      "title": "MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2021-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03833167",
      "title": "Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)",
      "status": "COMPLETED",
      "last_update": "2026-03-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007744",
      "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04301011",
      "title": "Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04305795",
      "title": "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04348916",
      "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04454489",
      "title": "Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition",
      "status": "COMPLETED",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04576091",
      "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04616248",
      "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799054",
      "title": "A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04808999",
      "title": "Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04812535",
      "title": "Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.",
      "status": "TERMINATED",
      "last_update": "2025-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05220748",
      "title": "RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC",
      "status": "WITHDRAWN",
      "last_update": "2023-04-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256381",
      "title": "A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05358938",
      "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05721755",
      "title": "Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06036836",
      "title": "Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)",
      "status": "COMPLETED",
      "last_update": "2026-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041802",
      "title": "A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06295809",
      "title": "A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)",
      "status": "TERMINATED",
      "last_update": "2026-05-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06580054",
      "title": "Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PUCOTENLIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07394244",
      "title": "Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SASANLIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04254107",
      "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2025-02-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}